Filing Flows › Companies › Evommune › Report card
Evommune earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate1 of 3 reports beat the EPS estimate
Evommune (EVMN) beat the analysts' EPS estimate in 1 of its last 3 reports (33%), by -24.6% on average. Next report: Nov 16, 2026, analysts expect EPS −$0.83.
Beat rate33% of 3
Average surprise-24.6%
Next reportNov 16, 2026
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue reported |
|---|---|---|---|---|---|
| Q to Jun 2026 | Aug 6, 2026 | −$0.67 | −$0.89 | -32.8% | — |
| Q to Dec 2025 | Mar 5, 2026 | −$0.84 | −$1.43 | -69.8% | — |
| Q3 2025 | Dec 11, 2025 | −$11.36 | −$8.07 | +28.9% | $10.0M |
Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Evommune: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.